A Patient With Multiple Myeloma, Amyloidosis and Light-Chain Deposition Disease in Kidneys With a Long Survival

Acta Haematol. 1999;101(4):202-5. doi: 10.1159/000040954.

Abstract

We report a case of a 39-year-old man with lambda-light-chain multiple myeloma, nephrotic syndrome due to lambda-light-chain deposition disease in kidneys and amyloidosis in other tissues. The patient was treated with melphalan and prednisone for 1 year. After that, he was administered interferon-alpha2b (IFN-alpha2b; 3 MU, 3 times a week) as maintenance therapy for 2 years. At present, 5 years and 6 months after the initial diagnosis, the patient receives IFN-alpha2b (3 MU, twice a week) and remains in complete haematological remission.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amyloidosis / complications
  • Amyloidosis / drug therapy*
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Immunoglobulin Light Chains / metabolism*
  • Interferon-alpha / therapeutic use*
  • Male
  • Melphalan / therapeutic use
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / metabolism
  • Nephrotic Syndrome / complications
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / metabolism
  • Prednisone / therapeutic use
  • Remission Induction
  • Survivors

Substances

  • Antineoplastic Agents
  • Immunoglobulin Light Chains
  • Interferon-alpha
  • Melphalan
  • Prednisone